Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cumberland Pharmaceuticals, a Tennessee-based specialty pharmaceutical company, has introduced a new formulation treatment for acetaminophen poisoning, Acetadote (acetylcysteine) Injection.
Subscribe to our email newsletter
Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury.
The company has received US Food and Drug Administration approval for this new formulation in January this year.
Following the approval, the new formulation of Acetadote (acetylcysteine) Injection replaces the previous marketed product.
Cumberland Pharma CEO AJ Kazimi said they are pleased to make this next generation of Acetadote available to the hospital community and the growing number of patients who will benefit from it.
"This launch marks an important milestone in our strategy to support our products by improving upon existing formulations and expanding into new patient populations," Kazimi said.